245 AS101 is a phase I trial of BIIB078, which targets toxic RNA from hexanucleotide repeats while preserving normal C9ORF72 proteins, administered intrathecally to adults with C9ORF72-mutated ALS, sponsored by Biogen (NCT03626012). The gene discussed is C9orf72; the disease is amyotrophic lateral sclerosis.